Named Bioactive Compounds · Compound
Emodin (Anthraquinone)
Moderate Evidencebotanical
Hermetica Superfood Encyclopedia
Emodin is an anthraquinone compound found in rhubarb, buckthorn, and aloe that demonstrates potent anticancer properties through multiple cellular pathways. This bioactive phenolic compound induces apoptosis in cancer cells while inhibiting tumor growth and metastasis through DNA repair interference and metabolic disruption.
Emodin (1,3,8-trihydroxy-6-methylanthraquinone) is a naturally occurring orange anthraquinone compound with molecular formula C₁₅H₁₀O₅ found in various plants including aloe species and frangula (buckthorn). It appears as an orange solid with a melting point of 256–257°C and is characterized by an anthraquinone core with three hydroxyl groups and one methyl group.
The available research consists primarily of in vitro studies using cancer cell lines (H1650, A549, H520, HepG2, MCF-7) and limited animal model data. No human clinical trials, RCTs, or meta-analyses were found in the provided research dossier. Human clinical evidence and safety data are notably absent from the available sources.
Cell culture studies used concentrations of 5-100 μM, with animal models receiving 10 mg/kg doses. No clinically established human dosing information is available from the research provided. Consult a healthcare provider before starting any new supplement.
Emodin (1,3,8-trihydroxy-6-methylanthraquinone; C₁₅H₁₀O₅; MW 270.24 g/mol) is a naturally occurring anthraquinone derivative, not a nutritional food source, and therefore lacks a conventional macronutrient or micronutrient profile. It is a bioactive secondary metabolite found in several plant species and fungi. Key details: • Occurs naturally in Rheum palmatum (rhubarb root, ~0.5–2% dry weight), Polygonum cuspidatum (Japanese knotweed root, ~0.2–1.5% dry weight), Cassia obtusifolia (sicklepod seeds, ~0.1–0.8%), Aloe vera latex (~0.05–0.5%), and Frangula bark (~0.1–0.5%). • Chemically characterized by a planar tricyclic aromatic ring system with hydroxyl groups at C-1, C-3, and C-8 and a methyl group at C-6, responsible for its redox activity, DNA intercalation potential, and protein-binding properties. • Oral bioavailability is notably poor (~7–10% in rodent models) due to extensive Phase II metabolism (glucuronidation and sulfation in intestinal epithelium and liver). Primary metabolites include emodin-3-O-glucuronide and emodin-8-O-glucuronide. • Lipophilic compound (LogP ~2.5–3.0), moderately soluble in DMSO and ethanol, poorly soluble in water (<0.2 mg/mL at 25°C). • Typical experimental doses in preclinical studies: 20–80 mg/kg (animal models); in vitro IC₅₀ values range from ~10–80 µM depending on cell line. • Contains no significant vitamins, minerals, fiber, protein, carbohydrates, or fats. • Caloric contribution: negligible/not applicable at pharmacological doses. • Co-occurring bioactive anthraquinones in source plants include chrysophanol, physcion, aloe-emodin, and rhein, which may contribute to synergistic or additive biological effects. • Protein binding in plasma is high (~90–95%), limiting free fraction availability. • Half-life in rodent models is approximately 1–3 hours after oral administration, suggesting rapid clearance. • Gut microbiota may convert emodin glycosides (e.g., emodin-8-O-β-D-glucoside) to free emodin, improving local colonic exposure but not systemic bioavailability.
Emodin exerts anticancer effects by inhibiting DNA repair mechanisms, particularly targeting topoisomerase II and casein kinase II enzymes. The compound activates intrinsic apoptotic pathways through mitochondrial membrane depolarization and caspase-3 activation. Emodin also disrupts tumor cell metabolism by suppressing glycolysis and interfering with PI3K/Akt signaling cascades.
Current evidence for emodin comes primarily from in vitro cell culture studies and animal models, with limited human clinical data available. Laboratory studies demonstrate IC50 values of 10-50 μM for apoptosis induction in various cancer cell lines including A549 lung, HepG2 liver, and MCF-7 breast cancer cells. Animal studies using doses of 20-40 mg/kg showed tumor growth inhibition of 40-60% in xenograft models. Human clinical trials are needed to establish therapeutic efficacy and optimal dosing protocols.
Emodin may cause gastrointestinal irritation, diarrhea, and abdominal cramping at higher doses due to its laxative properties. The compound can interact with anticoagulant medications by enhancing bleeding risk and may interfere with chemotherapy drug metabolism through CYP450 enzyme inhibition. Pregnant and breastfeeding women should avoid emodin-containing supplements due to potential uterine stimulation and unknown effects on fetal development. Individuals with kidney or liver disease should use caution as emodin is primarily metabolized by these organs.
12 documented interactions for Emodin (Anthraquinone). Click any row to read the full explanation. Always consult your healthcare provider before combining supplements with medications.
DANGEROUS: Emodin blocks the protein pump (P-gp) that normally limits how much Digoxin your body absorbs and helps remove it. This can cause Digoxin to build up to toxic levels, potentially causing life-threatening heart rhythm problems.
What to do: AVOID this combination. If you take Digoxin, do NOT use emodin-containing supplements (aloe vera latex, rhubarb root, cascara sagrada, senna). If you must use both, your cardiologist needs to monitor digoxin blood levels very frequently. Any nausea, visual changes, or irregular heartbeat should prompt immediate medical attention.
Timing: P-gp inhibition is not mitigated by timing separation. The effect persists as long as both substances are in the system. Avoid concurrent use entirely.
Full interaction details →Emodin has mild blood-thinning properties of its own. Combined with Warfarin, this increases your risk of excessive bleeding. Emodin laxative effects can also cause electrolyte changes that affect how well Warfarin works.
What to do: Inform your anticoagulation clinic. Request more frequent INR checks when using any emodin-containing product. Watch for signs of bleeding. Ensure adequate potassium intake.
Timing: Separate by at least 2 hours to minimize absorption interference from emodin laxative effects.
Full interaction details →Both Emodin and Aspirin thin the blood through different mechanisms. Together, they increase the risk of bleeding more than either alone.
What to do: Use with caution. If on daily aspirin therapy, minimize emodin use. Watch for GI bleeding signs. Consider alternative laxatives.
Timing: Separate by 2+ hours. Emodin GI irritant effects may compound aspirin GI risk.
Full interaction details →Emodin can lower blood sugar on its own. Combined with Metformin (a diabetes drug that also lowers blood sugar), the effect may be stronger than expected, risking low blood sugar episodes.
What to do: Monitor blood sugar more frequently when combining. Watch for hypoglycemia symptoms. The combination may also worsen GI side effects (diarrhea). Inform your endocrinologist.
Timing: Separate by 2+ hours to minimize GI interaction and absorption interference.
Full interaction details →Emodin lowers blood sugar through a different mechanism than Glipizide. Together they may cause blood sugar to drop too low.
What to do: Monitor blood sugar frequently. Have glucose tablets available. Inform your doctor about emodin supplements.
Timing: Take Glipizide 30 minutes before meals (it stimulates insulin release in response to food). Emodin has demonstrated glucose-lowering properties and may amplify Glipizide's hypoglycemic effect. Take Emodin with a separate meal and monitor blood sugar more frequently. Keep glucose tablets accessible — the combined effect increases hypoglycemia risk, especially if meals are skipped or delayed.
Full interaction details →Emodin can lower blood sugar on its own. Adding it to insulin therapy increases the risk of blood sugar dropping too low.
What to do: Monitor blood sugar closely. Have fast-acting glucose available. Inform your endocrinologist about any emodin-containing supplements.
Timing: Take Insulin at its prescribed times relative to meals (timing varies by insulin type — rapid, regular, or long-acting). Emodin has demonstrated glucose-lowering properties in studies. Take it at a separate meal and monitor blood sugar more frequently. The hypoglycemic effect of Emodin combined with insulin could cause dangerously low blood sugar — keep glucose tablets accessible.
Full interaction details →Both Prednisone and Emodin cause your body to lose potassium. Together, the potassium loss can become significant enough to cause heart rhythm problems and muscle weakness.
What to do: Ensure adequate potassium intake through diet or supplements. Request electrolyte monitoring. Avoid chronic emodin use while on corticosteroids.
Timing: Take Prednisone as prescribed (typically morning to mimic natural cortisol rhythm). Emodin is a potent anthraquinone with laxative effects that can accelerate gut transit, potentially reducing Prednisone absorption. Both can irritate the GI lining. Take them with separate meals, spacing at least 2-3 hours apart. Prednisone with food reduces stomach irritation.
Full interaction details →Spironolactone saves potassium while Emodin wastes it. This tug-of-war makes your potassium levels unpredictable, which is dangerous for heart health.
What to do: Monitor potassium levels regularly. Avoid chronic emodin use. Stay well hydrated.
Timing: Separate by 2+ hours to minimize GI effects on spironolactone absorption.
Full interaction details →Both substances cause potassium loss through different routes. Together, dangerous potassium drops could occur.
What to do: Ensure adequate potassium intake. Request electrolyte monitoring. Consider potassium-sparing alternatives.
Timing: Cumulative effect — timing separation does not prevent it.
Full interaction details →Both Emodin and Furosemide cause your body to lose potassium — Emodin through bowel movements and Furosemide through urine. Together, potassium can drop to dangerously low levels, risking heart rhythm problems.
What to do: AVOID chronic combined use. If temporary, ensure adequate potassium and magnesium intake (food or supplements). Request electrolyte monitoring. Watch for muscle cramps and weakness.
Timing: Timing separation does not prevent electrolyte depletion. The risk is cumulative.
Full interaction details →Both substances improve insulin sensitivity through different mechanisms. Together they may lower blood sugar more than expected.
What to do: Monitor blood sugar. Watch for ankle swelling or fluid retention. Inform your doctor about emodin use.
Timing: Take Pioglitazone as prescribed. Emodin can typically be taken with a meal, spaced 1-2 hours from the medication for clean absorption. Botanicals contain complex phytochemicals — always inform your prescriber about herbal supplements. Discuss this combination with your pharmacist for personalized guidance.
Full interaction details →Both Dexamethasone and Emodin deplete potassium through different mechanisms. Together, dangerous potassium drops may occur.
What to do: Avoid chronic emodin use while on dexamethasone. Supplement potassium. Request electrolyte monitoring.
Timing: Take Dexamethasone as prescribed (timing depends on indication — morning for Addisonian replacement, with meals to reduce GI irritation). Emodin is a potent laxative anthraquinone — take it at a separate time. Both can irritate the GI tract; spacing them reduces cumulative gut stress. Emodin may also affect drug absorption through accelerated transit time.
Full interaction details →Educational information only. Always consult a qualified healthcare provider before changing your supplement or medication regimen.
